A novel clinical prognostic index for patients with advanced gastric cancer: possible contribution to the continuum of care
-
Published:2021-10
Issue:5
Volume:6
Page:100234
-
ISSN:2059-7029
-
Container-title:ESMO Open
-
language:en
-
Short-container-title:ESMO Open
Author:
Shimozaki K.ORCID,
Nakayama I.ORCID,
Takahari D.ORCID,
Kamiimabeppu D.,
Osumi H.,
Wakatsuki T.,
Ooki A.,
Ogura M.,
Shinozaki E.,
Chin K.,
Yamaguchi K.
Subject
Cancer Research,Oncology
Reference36 articles.
1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008;Ferlay;Int J Cancer,2010
2. Gastric cancer;Van Cutsem;Lancet,2016
3. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial;Wilke;Lancet Oncol,2014
4. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial;Kang;Lancet,2017
5. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial;Shitara;Lancet Oncol,2018
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献